Related Experiment Videos
HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention
D C Hess1, A M Demchuk, L M Brass
1Department of Neurology, Medical College of Georgia and Veterans Affairs Medical Center, Augusta 30904, USA. dhess@neuro.mcg.edu
Insights
Statins show promise in preventing strokes, potentially through cholesterol reduction and other mechanisms. Further research is needed, especially in elderly populations.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Pharmacology
Background:
- Statins are a class of drugs used to lower cholesterol.
- Coronary artery disease (CAD) is a major risk factor for stroke.
- Emerging evidence suggests statins may have neuroprotective effects beyond lipid lowering.
Purpose of the Study:
- To review the evidence for statin use in stroke prevention.
- To explore potential non-cholesterol-related mechanisms of statin action in stroke.
- To identify gaps in current research regarding statins and stroke.
Main Methods:
- Review of randomized controlled trials (RCTs) in middle-aged patients with CAD.
- Analysis of preclinical studies using murine stroke models.
- Evaluation of evidence for specific statins like pravastatin and simvastatin.
Main Results:
- Statins reduce stroke incidence in middle-aged patients with CAD.
- Stroke risk reduction may involve pleiotropic effects on endothelial cells, macrophages, platelets, and smooth muscle cells.
- Statins demonstrated neuroprotective effects by reducing cerebral infarction size in a mouse model.
Conclusions:
- Pravastatin and simvastatin are effective for stroke prevention in specific patient groups.
- Statins offer benefits beyond lipid-lowering, suggesting pleiotropic effects.
- Further investigation of statins in stroke populations, particularly the elderly, is warranted.
Abstract:
Statins represent a promising class of agents to prevent stroke. In randomized trials of middle-aged patients with coronary artery disease, statins reduce the incidence of stroke. The reduction in stroke may not be solely related to cholesterol or low-density lipoprotein reduction but may involve nonsterol mechanisms effects on endothelial cells, macrophages, platelets, and smooth muscle cells. Statins also reduce the size of cerebral infarction in a murine stroke model, suggesting a neuroprotective effect. The best current evidence for stroke prevention is with pravastatin and simvastatin. Pravastatin reduces the risk of stroke in patients with coronary artery disease and average cholesterol levels; simvastatin reduces the risk of the combined endpoint of stroke and transient ischemic attack in hypercholesterolemic patients with coronary artery disease. Future studies of statins are needed in stroke populations, particularly the elderly.